The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/20 - 1/50.
1/1000 - 1/5000. Detects a band of approximately 62 kDa (predicted molecular weight: 61 kDa).
Application notesIs unsuitable for Flow Cyt,ICC or IHC.
FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53. Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily. Contains 1 FHA domain. Contains 1 protein kinase domain.
Post-translational modificationsPhosphorylated by PLK4.
Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
Western blot - Anti-Chk2 (phospho T68) antibody [Y171] (ab32148)
All lanes : Anti-Chk2 (phospho T68) antibody [Y171] (ab32148) at 1/5000 dilution
Lane 1 : HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate Lane 2 : Whole cell lysate from HEK-293 (Human epithelial cell line from embryonic kidney) cells, treated with UV at 60J/m2 for 2 hours. Lane 3 : Whole cell lysate from HEK-293 (Human epithelial cell line from embryonic kidney) cells, treated with UV at 60J/m2 for 2 hours. Membrane incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
References for Anti-Chk2 (phospho T68) antibody [Y171] (ab32148)
This product has been referenced in:
Li WF et al. WISP-1 contributes to fractionated irradiation-induced radioresistance in esophageal carcinoma cell lines and mice. PLoS One9:e94751 (2014).
Read more (PubMed: 24728101) »
Zhang D et al. Sterigmatocystin-induced DNA damage triggers G2 arrest via an ATM/p53-related pathway in human gastric epithelium GES-1 cells in vitro. PLoS One8:e65044 (2013).
Read more (PubMed: 23705030) »